The increasing trend towards high-priced medicines threatens the financial sustainability of health care systems. In a study, the Austrian Institute for Health Technology Assessment (AIHTA) has now developed – as an example – a good practice model with which the risks can be shared equally between the public sector and pharmaceutical companies.